Abstract
Our aim was to study the feasibility of an intensified intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) schedule with the aim to escalate dose intensity (DI). Twenty-three premenopausal breast cancer patients received 6 cycles of adjuvant CMF intravenously on days 1 and 8 every 3 weeks and granulocyte colony-stimulating factor days 9–18. Endpoints were DI and toxicity. Twenty-one out of 23 patients (91%) received the projected total dose and reached ≥ 85% of the projected DI. Compared to ‘classical’ CMF, all patients reached ≥ 111% DI. Nine patients received the planned schedule without delay. Thirteen patients (57%) were treated for infection and four patients (17%) were hospitalized for febrile neutropenia. Twelve patients received red blood cell transfusions (52%). Radiation therapy (n = 6) had no adverse impact on dose intensity or haematological toxicity. This dose-intensified CMF schedule was accompanied by enhanced haematological toxicity with clinical sequelae, namely fever, intravenous antibiotics and red blood cell transfusions, but allows a high dose intensity in a majority of patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ang PT, Buzdar AU, Smith TL, Kau S and Hortobagyi GN (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7: 1677–1684
ASCO Ad Hoc Colony-Stimulating Factor Guideline Expert Panel (1994) The American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508
Biesma B, Vellenga E, Willemse PH and De Vries EG (1992) Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression. Crit Rev Oncol Hematol 13: 107–134
Bonadonna G and Valagussa P (1981) Dose–response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
Bronchud MH, Howell A, Crowther D, Hopwood P and Souza L (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60: 121–125
Cooper MR, Rhyne AL, Muss HB, Ferree C, Richards F 2d, White DR, Stuart JJ, Jackson DV, Howard V, Shore A and Spurr CL (1981) A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47: 2833–2839
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V and Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164–170
De Graaf H, Willemse PH, Bong SB, Piersma H, Tjabbes T, van Veelen H, Coenen JL and de Vries EG (1996) Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 53: 289–294
Engelsman E, Klijn JCM, Rubens RD, Wildiers J, Beex LVAM, Nooij MA, Rotmensz N and Sylvester R (1991) ‘Classical’ CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 27: 966–970
Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M and Gelber RD 1998 a) Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike?. Ann Oncol 9: 489–493
Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M and Gelber RD 1998 b) Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol 16: 1358–1362
Holland JF, Glidewell O and Cooper RG (1980) Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast. Surg Gynecol Obstet 150: 817–821
Hryniuk WM and Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1287
Hryniuk WM and Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162–1170
Hryniuk WM, Figueredo A and Goodyear M (1987) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14: 3–11
Levine JF, Coleman NC, Cox RS, Ray GR, Rogoway WM, Martinez A and Stockdale FE (1984) The effect of post-operative and primary radiation therapy on delivered dose of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in breast cancer. Cancer 53: 237–241
Lieschke GJ and Burgess AW (1992) Drug therapy: granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor (Second of two parts). N Engl J Med 327: 99–106
Lindeman GJ, Boyages J, Driessen C and Langlands AO (1992) Intravenous or oral adjuvant CMF for node-positive breast cancer. Aust N Z J Surg 62: 556–562
Neidhart J, Mangalik A, Kohler W and Langlands AO (1989) Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 7: 1685–1692
Pronzato P, Miglietta L, Rubagotti A, Bertelli G, Queirolo P, Guenzi M, Sertoli MR, Vitale V and Rosso R (1993) Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity. Am J Clin Oncol 16: 58–60
Ribas A, Albanell J, Bellmunt J, Sole-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J and Baselga J (1996) Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 14: 1573–1580
Tannock IF, Boyd NF, De Boer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D and Sutherland H (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377–1387
Tjan-Heijnen VC, Biesma B, Festen J, Splinter TA, Cox A, Wagener DJ and Postmus PE (1998) Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol 16: 2708–2714
WHO (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48 Geneva: WHO
Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Colango Ballow A, Frei III E and Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253–1259
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Bos, A., Graaf, H., Vries, E. et al. Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer 82, 1920–1924 (2000). https://doi.org/10.1054/bjoc.2000.1242
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1242